Gene therapy developer Krystal Biotech (NASDAQ: [[ticker:KRYS]]) has appointed Jennifer Chien to the newly created role of chief commercial officer. She comes to Pittsburgh-based Krystal from the Genzyme unit of Sanofi (NYSE: [[ticker:SNY]]), where she was vice president and head of genetic diseases. Krystal’s lead therapeutic candidate, KB103, is a topical gene therapy in mid-stage testing for dystrophic epidermolysis bullosa, a rare genetic disease affecting the skin.
Author: Frank Vinluan
Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times.
View all posts by Frank Vinluan
